The stress-activated protein kinase, c-Jun N-terminal kinase (JNK), has been implicated in the process of cardiac hypertrophy and apoptosis, yet the specific roles of JNK in heart failure are unclear. To determine the effects of JNK activation in intact heart, we established transgenic animals using a Cre/loxP-mediated gene switch approach to achieve targeted expression of an upstream activator, mitogen-activated protein kinase kinase 7 (D) (MKK7D), in ventricular myocytes. MKK7D expression led to significant JNK activation, robust induction of the fetal gene program, and contractile dysfunction. The animals died ϳ7 weeks after birth with signs of congestive heart failure. Doppler mode echocardiography revealed a marked stiffening of JNK-activated hearts that was associated with the remodeling of specific extracellular matrix components. Gene expression analysis of MKK7D hearts revealed up-regulation of transforming growth factor ␤ signaling, offering a potential molecular mechanism underlying changes in extracellular matrix composition. In addition, we demonstrated that JNK activation led to specific loss of connexin 43 protein and gap junctions without affecting the expression or localization of other key intercalated disc proteins. This specific and localized gap junction remodeling resulted in significant slowing of ventricular electrical conduction in JNK-activated hearts. These results represent the first characterization of JNK-mediated cardiac pathology in vivo and support an important role for JNK signaling in specific aspects of cardiac remodeling in the pathogenesis of cardiac disease.
The development of heart failure involves a multistep remodeling process in response to pathological stressors, from compensatory hypertrophy to decompensated chamber remodeling. Stress-induced signaling pathways play an important role in these responses and may contribute to specific features of the remodeling process (1) . JNK 1 is a member of the highly conserved mitogen-activated protein kinase family of intracellular signaling molecules that are activated by a variety of physical, chemical, and biological stressors such as ultraviolet radiation, heat shock, osmotic stress, cytokines, and endotoxins (reviewed in Ref.
2). Signals transduced by this kinase family ultimately lead to the activation of stress response genes and the synthesis of proteins important for cellular adaptation to the stress stimulus.
In the heart, JNK is activated in response to a variety of pathological insults such as hypertension, ischemia/reperfusion injury, and myocardial infarction (3) (4) (5) . Several studies have implicated JNK signaling as a key mediator of pathological cardiac remodeling and heart failure. An important role for JNK signaling has been demonstrated in cardiac hypertrophy (6 -8) as well as cardiomyocyte apoptosis (9) . Recently, Molkentin and co-workers (10) also demonstrated an anti-hypertrophic role for JNK signaling using loss of function approaches. Thus, considerable evidence implicates JNK signaling in cardiac pathogenesis, yet the effects of JNK activation on cardiac function and morphology have not been fully established in vivo, and the role of JNK signaling in different aspects of cardiac remodeling during heart failure remains unclear.
We have previously linked JNK activation to a specific aspect of pathological cardiac remodeling, stress-induced down-regulation of the gap junction protein connexin 43 (Cx43) (11) . Loss of gap junctions is a common feature of the failing heart (12) and has been demonstrated to contribute importantly to arrythmogenesis (13) . In this report, we examined the specificity of JNKinduced intercalated disc remodeling for Cx43 and demonstrated the functional effects of JNK-induced loss of Cx43 expression on action potential propagation in the intact heart.
Efforts to establish transgenic animals with targeted activation of the JNK pathway in heart were complicated by difficulty in generating stable transgenic lines due to severe cardiac phenotypes that resulted in premature death (14) . To avoid such obstacles, we employed a Cre/loxP-mediated gene switch strategy, which we had used successfully to study p38 mitogenactivated protein kinase (15) and Ras (16) to target expression of MKK7D, a constutively active MKK7 mutant, in ventricular myocytes. MKK7 can activate all three known JNK isoforms (17) , with JNK1 and JNK2 the highly expressed isoforms in heart (10, 18) . This unique animal model allowed us to perform a comprehensive analysis at morphological, molecular, and functional levels. Contrary to previous reports in cultured cardiac myocytes, our results demonstrated that JNK activation is not sufficient to induce hypertrophy or cardiomyocyte apoptosis in vivo. Instead, activation of JNK leads to myocardial remodeling of the extracellular matrix (ECM) and gap junctions that results in a loss of ventricular wall compliance and a significant decrease in epicardial conduction velocity. This in vivo evidence suggests that JNK signaling may play a vital role in mediating specific aspects of pathological remodeling associated with heart failure.
MATERIALS AND METHODS
Generation of Transgenic Animals-The cloning of an ␣-myosin heavy chain-flox-MKK7D construct and the Cre-mediated removal of GFP (gene-switch) have been described previously (11, 15, 16) . Briefly, the cDNA fragment encoding human mitogen-activated protein kinase kinase D (MKK7D) (Ser 271 and Thr 275 to Asp) mutant was inserted into the pflox vector (6) . Transgenic animals harboring the floxed-MKK7D transgene were identified by Southern blots and PCR as described (15) , and colonies were established in a Blackswiss background. The floxed-MKK7D mice were then bred with mice possessing the gene coding for Cre recombinase under the regulation of the myosin light chain-2v promoter (MLC-2v/Cre) (19) . The GFP-expressing floxed-MKK7D and Cre-expressing MLC-2v/Cre mice have no detectable abnormal cardiac phenotype (20) . 2 The double transgenic offspring (MKK7D) of the floxed-MKK7D mice and MLC-2v/Cre mice were identified by PCR from tail DNA as described previously (15) and were analyzed between 6 and 8 weeks after birth using age/sex-matched littermates with genotypes of floxed-MKK7D, MLC-2v/Cre, and wild type as controls.
Protein and RNA Dot-blot Analysis-Whole hearts were excised from mice and snap frozen in liquid nitrogen. To obtain protein extracts, left ventricles were pulverized on dry ice and homogenized in cell lysis buffer containing 20 mM Tris (pH 7.4), 150 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM ␤-glycerophosphate, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, and a protease inhibitor mixture (Roche Applied Science). After 10-min microcentrifugation (10,000 rpm) at 4°C, the supernatants were frozen on a dry ice/ethanol bath and stored at Ϫ80°C. Protein samples were subjected to SDS-PAGE, transferred to nitrocellulose membranes, and blotted with antibodies against GFP (Clontech), MKK7 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), p38, phospho-p38, ERK, phospho-ERK, JNK, and phospho-JNK (Cell Signaling, Inc.). These JNK and phospho-JNK antibodies are specific for p46 and p54 JNK, composed primarily of JNK1 and JNK2, respectively. Signals were detected using the Pico West System (Pierce), exposed to x-ray film, and quantified using Scion NIH Image software. RNA samples were prepared from the same heart tissues using TRIZOL reagent (Invitrogen) according to the manufacturer's recommended protocol. RNA dot-blot analysis was performed as previously described (15) using a set of oligonucleotide probes (21) . Briefly, 2 g of total RNA isolated from the hearts of the animals was blotted on cellulose membrane (Schleicher & Schü ll) and hybridized with 32 P-labeled oligonucleotide at various lengths that complement the coding sequence of the target mRNAs. Hybridization signals were quantified with a PhosphorImager (Amersham Biosciences) and were presented as relative pixel value normalized against GAPDH.
Histological Analysis-Hearts were perfusion fixed in 4% paraformaldehyde/phosphate-buffered saline followed by overnight incubation in the same fixative. Hearts were dehydrated and embedded in paraffin, and 6-m-thick sections were cut. Deparaffinized and rehydrated heart sections were stained with Alexa-568-conjugated wheat germ agglutinin to outline myocyte membranes and were viewed on a Zeiss IM-35 fluorescence microscope equipped with a Spot CCD camera (Diagnostic Instruments). Myocyte area was calculated from 15 myocytes/field from five random fields of view for each of three MKK7D and three control hearts using software supplied by the camera manufacturer. Collagen content was analyzed by picrosirius red staining of deparaffinized sections of left ventricle performed as described previously (22) and analyzed by confocal microscopy using a Zeiss 410 confocal microscope.
Immunohistochemistry-Immunostaining of Cx43 and cadherins was performed using paraffin embedded sections as previously described (23) . Double labeling of Cx43 and ZO-1, as well as fibronectin immunostaining, was performed using frozen ventricular sections as described (24) . Immunoreactive signal was detected with polyclonal antibodies to fibronectin (Sigma), pan cadherin, made against the COOH-terminal amino acids of chicken N-cadherin (Sigma) or ZO-1 (Zymed Laboratories Inc.) and a monoclonal Cx43 antibody (Chemicon) followed by Alexa-488 and Alexa-568-conjugated secondary antibodies (Molecular Probes, Inc., Eugene, OR). All images were captured using identical settings on a Zeiss 410 confocal microscope.
TUNEL Assay-Hearts were processed as described above for histologic analysis. TUNEL labeling was performed using an ApopTag fluorescein in situ apoptosis detection kit (Intergen) and following the manufacturer's protocol. Sections incubated with 10 units/ml deoxyribonuclease I (Sigma) for 10 min served as positive controls. Sections were counterstained using antifade mounting medium containing 0.5 g/ml propidium iodide and coverslipped. Staining was viewed with a Zeiss IM-35 fluorescence microscope, and images of six random fields for each sample were captured with a Spot CCD camera (Diagnostic Instruments). Results are presented as TUNEL-positive cells/total nuclei.
Echocardiography and Hemodynamic Measurement-Noninvasive transthoracic echocardiograms were performed in 6-week-old conscious animals (Sequoia, Acuson, Mountain View, CA) as described (25) . Wild type, MLC2v/Cre, and floxed-MKK7D transgenic mice were grouped together as controls for echocardiography, since MLC/2v/Cre and floxed-MKK7D mice have no detectable cardiac abnormalities (11, 20) . Hemodynamic measurements were obtained from five wild type controls and two MKK7D animals at 6 weeks of age. Animals were anesthetized, and hemodynamics were measured using a pressures-volumes catheter inserted into the left ventricle as previously described (15) .
Microarray and Real Time RT-PCR Analysis-RNA samples from left ventricles of MKK7D transgenic and age-and sex-matched nontransgenic littermate control hearts were extracted using Trizol reagent and purified with an Rneasy Mini kit (Qiagen). Transcriptional profiling was performed using murine genome U74A version 2 GeneChip arrays (Affymetrix) exactly as previously described (26) . Data were analyzed with Data Mining Tool 3.0 (Affymetrix), and differentially expressed transcripts are described by -fold change control as recommended by Affymetrix (26) . Data were further analyzed and grouped into functionally related groups using GenMAPP software (Gladstone Institutes) (27) . Reverse transcription of 5 g of total RNA isolated from left ventricles as described above was performed using the Superscript First-Strand Synthesis System and supplied oligo(dT) primers (Invitrogen). Relative abundance of gene expression was quantified by real time RT-PCR (iCycler iQ real time PCR; Bio-Rad) using IQ SYBR Green Supermix (Bio-Rad). Primers used for real time RT-PCRs specific for transforming growth factor ␤1 (TGF-␤1) (28), TGF-␤2, TGF-␤3, TGF-␤ RII (29) , and TGF-␤ RI (30) have been described previously. Equal starting amounts of RNA were insured by normalizing to GAPDH using the primers GAPDH forward (5Ј-TCCTGCACCAC-CAACTGCTTAG-3Ј and GAPDH reverse 5Ј-GATGACCTTGCCCA-CAGCCTTG-3Ј. All reactions were performed using the following parameters: 94°C for 10 min followed by 40 cycles of 94°C for 25 s, 55°C for 20 s, and 72°C for 45 s.
Optical Mapping-Optical mapping experiments were performed as described previously (31) . Conduction velocity was measured by averaging local velocity vectors from contiguous sites transverse and longitudinal to cardiac fibers. Action potential duration (APD) was measured as the time of activation to 70% repolarization, and action potential rise time was corrected for optical blurring as described previously (32) .
Statistical Analysis-Results were expressed as mean Ϯ S.D. Statistical significance was assessed by Student's paired two-tailed t test with a p value of Ͻ0.05 considered to be statistically significant.
RESULTS

Cardiac Pathology Induced by Targeted Activation of JNK in Ventricular Myocytes in
Vivo-A transgenic model with targeted activation of JNK in ventricular myocytes was established using a Cre/loxP-mediated gene switch approach as described (11) . Double transgenic offspring (MKK7D) had diminished GFP expression and induction of MKK7D expression in the ventricles as a result of Cre-mediated DNA recombination (Fig. 1A) . MKK7D expression led to activation of both p46 (primarily JNK1) and p54 (primarily JNK2) as determined by immunoblotting with a phospho-JNK antibody, whereas total JNK protein levels remained unchanged in MKK7D hearts compared with controls (Fig. 1B) . Using total and phosphospecific antibodies against p38 and ERK, we also demon-strated the specificity of MKK7D for activating JNK in vivo without significant activation of p38 or ERK activities (Fig.  1B) . MKK7D mice died ϳ7 weeks after birth with signs of congestive heart failure, including increased lung weight/body weight ratio (Table I) , ascites, dyspnea, and lethargy (Supplemental Fig. 1 ). Cardiac morphology of MKK7D transgenic hearts was characterized by an enlargement of both left and right atria ( Fig. 2A) . Although MKK7D mice had a modest reduction in ventricular mass compared with controls, the difference was not statistically significant when normalized to body weight (Table I) . The cross-sectional area of ventricular myocytes from JNK-activated hearts was also unchanged compared with controls (210 Ϯ 70 m 2 (MKK7D) versus 206 Ϯ 71 (control) m 2 , p Ͼ 0.5, Fig. 2B ). Marker genes associated with hypertrophy and heart failure were induced, including atrial natriuretic factor, and the characteristic ␣-to ␤-myosin heavy chain isoform switch (Fig. 2C) . To assess possible cardiomyocyte apoptosis in response to JNK activation, TUNEL staining was performed on sections of MKK7D left ventricle. The number of apoptotic nuclei in JNK-activated heart was similar to that in controls (Fig. 3) , consistent with the modest decreases in ventricle wall thickness and lack of detectable replacement fibrosis in MKK7D hearts (see below) (Table II and Fig. 4) . These results suggest that JNK activation is not sufficient to induce apoptosis in vivo. Together, our findings indicate that activation of JNK in ventricular myocytes in vivo leads to phenotypic changes characteristic of congestive heart failure in the absence of ventricular hypertrophy or apoptosis.
Contractile Dysfunction and Chamber Remodeling of JNKactivated Transgenic Heart-Contractile function of JNK-activated hearts in intact animals was evaluated by echocardiography. As summarized in Table II , M-mode echocardiography confirmed our observations from morphometry and histology, demonstrating a decrease in ventricular chamber dimensions along with a modest decrease in ventricular wall thickness. With comparable decreases in both end-diastolic and end-systolic chamber dimensions, fractional shortening in MKK7D hearts was maintained compared with controls. To further assess cardiac function, transmitral Doppler echocardiography was performed (Table II) , which showed significant shortening in deceleration time of the early filling wave, suggesting a loss of chamber compliance and stiffening of the ventricle (33) . Consistent with Doppler measurements, in vivo hemodynamic measurements made using conductance catheter methods revealed substantially increased end-diastolic pressures (8.50 Ϯ 2.48 versus 20.3 Ϯ 2.14 mm Hg, control versus MKK7D, respectively) without an accompanying increase in end-diastolic volume (24.63 Ϯ 4.11 versus 10.60 Ϯ 2.14 l, control versus MKK7D, respectively). Interestingly, MKK7D hearts did not exhibit increased interstitial collagen content (Fig. 4A) , which is commonly associated with decreased ventricular compliance (34) . Instead, a marked increase in the ECM glycoprotein fibronectin was observed (Fig. 4B) . Together, these results demonstrate that JNK-activated hearts exhibit a substantial loss of compliance consistent with restrictive cardiomyopathy that may be contributed to by selective ECM remodeling.
Increased Transforming Growth Factor ␤ Signaling in JNKactivated Transgenic Heart-To gain insights into the molecular mechanisms underlying JNK-induced pathology, we used 
cDNA microarrays to analyze gene expression profiles in MKK7D and control hearts. Of the ϳ12,000 probe pairs on the Affymetrix U74Av2 GeneChip, 574 were increased, and 524 were decreased in at least five of six pairwise comparisons (three MKK7D and two control samples). Many of the changes can be validated by measurements from Northern, dot-blot, and real time RT-PCR assays (Supplemental Table I ). We used GenMAPP gene ontology software (Gladstone Institute) to identify patterns of change in biologically related gene families (27) . This approach revealed a marked increase in the expression of numerous genes involved in TGF-␤ signaling, including ligands, receptors, intermediate signaling molecules, and TGF-␤-dependent target genes (Table III) expression, which were not detected as significantly changed by microarray analysis, were shown to be modestly increased as measured by real time RT-PCR, perhaps reflecting the different sensitivities of the techniques. TGF-␤ signaling has been implicated as an important inducer of ECM remodeling in a variety of organ systems, including the heart (35). This finding suggests that JNK activation may play an important role in the coordinated induction of TGF-␤ signaling in the heart, which may represent a potential molecular mechanisms underlying altered ECM composition and chamber stiffening observed in JNK-activated hearts.
Gap Junction Remodeling and Cardiac Conduction Defects in MKK7D Transgenic
Heart-Recently, we identified JNK as an important mediator of stress-induced Cx43 down-regulation in cardiomyocytes and demonstrated that MKK7D transgenic ventricles have a substantial loss of Cx43 protein expression (10% of control littermates) (11) . To investigate whether JNKinduced Cx43 down-regulation is a specific process or due to a general loss of structural integrity at intercalated discs, we examined the organization of other intercalated disc proteins in MKK7D hearts (36) . As shown in Fig. 6 , expression and localization of both N-cadherin, a principal component of fascia adherens junctions, and ZO-1, a Cx43-associated scaffolding protein, were not altered in MKK7D hearts compared with controls.
Cx43 is a gap junction protein essential for electrical coupling of the ventricular myocardium (37, 38) . In order to provide direct assessment of electrical conduction, we measured epicardial conduction velocity in MKK7D and control hearts using a high resolution optical mapping technique (31) . Shown in Fig. 7A are representative action potentials recorded from MKK7D and control hearts stimulated at a cycle length of 130 ms. Although there was no change in the overall morphology of the action potential, APD was prolonged from 27 Ϯ 6 ms in controls to 37 Ϯ 6 ms in MKK7D hearts (p Ͻ 0.005). Representative maps of propagation demonstrate the expected elliptical spread of propagation from a point stimulus in both MKK7D and control hearts but with significant conduction slowing in MKK7D hearts as evident by crowding of activation isochrones (Fig. 7B) . Conduction velocity was consistently slower in MKK7D hearts compared with control, both transverse and longitudinal to cardiac fibers at all cycle lengths measured (Fig. 7C) . Furthermore, corrected action potential rise time was similar in MKK7D and control hearts (1.12 Ϯ 0.05 versus 1.06 Ϯ 0.12 ms, respectively; p ϭ 0.75), suggesting that conduction slowing was not attributable to alterations in sodium current. Together, our data suggest that loss of Cx43 in MKK7D ventricles appears to be a specific intercalated disc remodeling process rather than a consequence of disrupted structural integrity and provides direct in vivo evidence that JNK-induced loss of gap junctional protein may contribute to conduction defects in the stressed myocardium.
DISCUSSION
Using a Cre/loxP-mediated gene-switch strategy to target the activation of JNK to the intact ventricle, we have demonstrated that JNK activation in vivo 1) is not sufficient to induce cardiac hypertrophy or cardiomyocyte apoptosis; 2) leads to remodeling of the ECM, loss of ventricular compliance, restricted filling, and premature death with signs of congestive heart failure; and 3) specifically remodels gap junctions associated with slowing of action potential propagation. Together, our findings support an important role for JNK in mediating specific aspects of cardiac remodeling and provide the first in vivo evidence of the functional effects of JNK-induced pathological remodeling in the intact heart.
Reports on the role of JNK signaling in cardiac hypertrophy and apoptosis, both key components associated with the pathogenesis of heart failure, are conflicting. Here, we show that activation of JNK in vivo by transgenic expression of MKK7D induces expression of the fetal gene program associated with hypertrophy yet is not sufficient to induce an increase in myocyte size or ventricular wall thickness. Our findings are consistent with a recent report by Molkentin and colleagues showing that expression of an MKK7D-JNK1 fusion protein in vivo did not induce cardiac hypertrophy (10) . Furthermore, these authors showed that crossing MKK7-JNK1 mice with an activated calcineurin transgenic line previously shown to exhibit massive hypertrophy diminished the hypertrophic phenotype in double transgenic animals (10). These results, together with data demonstrating exacerbated hypertrophy in response to pressure overload in animals with a loss of function in JNK signaling, suggests that JNK activation opposes hypertrophy (10) . However, the observation that JNK activation induces the expression of the fetal-like gene expression profile characteristic of hypertrophy (Fig. 2C) (39) , together with our previous report that specific activation of JNK in cultured neonatal cardiomyocytes was sufficient to induce hypertrophy (6), suggests that JNK activation could potentially play an auxiliary role in hypertrophy through cross-talk with other signaling pathways, depending on the cellular context and nature of the hypertrophic stimuli. Last, the current model is not sufficient to dissect the potentially different role of JNK isoforms in the cardiac remodeling observed here. Further experiments incorporating isoform-specific manipulation, either through dominant negative mutation or targeted inactivation, will be needed to address such issues.
A striking morphological feature of MKK7D hearts is the enlarged atria. Since MKK7D expression is limited to the ventricular myocytes due to the tissue-specific expression pattern of the MLC-2v promoter (40, 41) , the enlargement is probably secondary to JNK-induced ventricular dysfunction. Indeed, the increased atrial mass could be primarily attributed to thrombosis, without a substantial difference in wall thickness between MKK7D and control atria (data not shown). 2 Thus, the enlargement of MKK7D atria is probably a consequence of higher filling pressures associated with decreased compliance of MKK7D ventricles, similar to that previously reported for ventricle-targeted expression of MKK3bE, MKK6bE, and H- Ras-v15 (15, 40) .
JNK signaling has been shown to be a critical mediator of apoptosis in many cell types (42) of JNK in cardiomyocyte apoptosis, however, is unclear. Several studies support a protective role for JNK activation in cultured myocytes (43) (44) (45) (46) , whereas others have shown JNK signaling to be proapoptotic in the setting of oxidative stress (9, 47) . Recent studies have begun to examine the role of JNK in cardiomyocyte apoptosis in vivo. Pressure overload in MEKK1Ϫ/Ϫ mice, defective in JNK-mediated signaling, showed increased cardiomyocyte apoptosis compared with wild type controls, suggesting a protective role for JNK signaling in response to hemodynamic stress (48) . In contrast, ischemiareperfusion-induced apoptosis was attenuated by JNK inhibition, suggesting JNK activation is proapoptotic (49) . These contrasting results indicate that the role of JNK may largely depend on the nature of the apoptotic stimulus. Whereas our findings suggest that JNK signaling is not sufficient to induce apoptosis in vivo, based on our experimental model, we cannot rule out an important role for JNK in apoptotic signaling in the setting of other pathophysiological stresses. Imposing apoptogenic stimuli on animal models with a gain of function in JNK signaling targeted to cardiac myocytes (such as the model characterized here) should provide further insight as to the pro-or antiapoptotic nature of JNK signaling in the heart.
Despite unaltered fractional shortening, MKK7D mice exhibited profound diastolic dysfunction and premature death with signs of congestive heart failure. Functional analysis in intact animals revealed that the MKK7D hearts were substantially less compliant. Surprisingly, this stiffness was not associated with increased interstitial collagen deposition that is often associated with decreased compliance but instead with marked interstitial fibronectin accumulation. Fibronectin is a major component of the noncollagenous ECM in the heart and functions as a link between the collagen matrix and the sarcolemmal membrane (50) . Increased fibronectin expression has been reported in heart failure patients (51) and several animal models of cardiac dysfunction (52) (53) (54) . Functionally, increased fibronectin expression would strengthen interactions between the collagen matrix and integrins on the myocyte surface, which has been shown to alter the viscoelastic properties of the myocardium (55) . Thus, the striking increase in fibronectin accumulation in JNK-activated hearts may contribute to the observed loss of compliance and cardiac dysfunction. viewed in Ref. 56) . Transgenic mice with TGF-␤ expression targeted to the liver developed myocarditis characterized by cellular infiltration and fibrosis (57) . Furthermore, treating rats with TGF-␤-neutralizing antibodies prevented fibrosis and diastolic dysfunction following pressure overload (58) . In contrast, mice with cardiac specific expression of a mature mutant of TGF-␤1 did not develop ventricular fibrosis or display a prominent cardiomyopathic phenotype but instead were characterized by atrial fibrosis and a decreased ability for cardiac wound healing (59) . Thus, whereas a wealth of data supports a critical role for TGF-␤ signaling in cardiac pathogenesis, the mechanisms underlying its action are unclear and may involve a coordinated regulation of the entire signal cascade.
Regulation of TGF-␤ signaling is complex, involving multiple levels of transcriptional and post-translational control (60) . Induced TGF-␤ signaling in JNK-activated heart was of particular interest, considering the well established link between TGF-␤ signaling and cardiac fibrosis, particularly fibronectin expression (61, 62) . Indeed, JNK signaling is implicated in transcriptional regulation of TGF-␤1 and TGF-␤2 via activation of its downstream substrates c-Jun and ATF2 (63, 64) . However, our data from microarray analysis suggests that JNK activation may also be responsible for a coordinated induction of TGF-␤ signaling, not only at the ligand level but also postranslational modification, receptors, and downstream signal transduction (Table III) . Whether common or separate regulatory mechanisms are employed in this coordinated regulation is unclear and should be of great interest for further investigation.
JNK-induced TGF-␤ signaling may increase fibronectin expression, either in cardiac fibroblasts or cardiomyocytes or both. Alternatively, JNK activation may induce fibronectin expression more directly by activation of the AP-1 complex that has been demonstrated as essential for fibronectin promoter activation in response to angiotensin II stimulation (62) . Further studies will be required to dissect which of these mechanisms are involved in JNK-activated hearts and give important insight into how JNK activation leads to specific ECM remodeling and loss of myocardial compliance.
A recent study from our laboratory has implicated JNK signaling as an important mediator of stress-induced loss of Cx43 expression in cardiac myocytes (11) . Activation of JNK by MKK7D expression in transgenic hearts down-regulates Cx43 protein expression to only 10% compared with control littermate hearts (11) . Despite this substantial loss of Cx43 expression, localization of adherens junctions and the Cx43-interacting protein, ZO-1, were unaltered in MKK7D hearts. These findings are consistent with a recent report demonstrating that structural domains of the intercalated disc are independent of the presence of gap junctions or Cx43 expression (65) . Our findings further suggest that JNK-mediated Cx43 down-regulation involves specific, localized remodeling of gap junctions in cardiac myocytes.
Considering the importance of Cx43 expression in electrically coupling working ventricular myocytes (13, 31, 66) , we sought to determine the functional consequences of JNK-induced Cx43 loss on conduction velocity in MKK7D hearts. The 40% slowing of conduction observed in JNK-activated hearts is consistent with previous reports of conduction slowing in mice in which Cx43 expression was decreased to comparable levels via a gene targeting approach (13) . Conduction slowing occurred in the absence of any change in action potential rise time, suggesting that it was unlikely to be due to impaired excitability of sodium current in MKK7D ventricles but rather was attributable to intercellular uncoupling. The explanation for the increase in APD in MKK7D hearts is unknown, but it could be contributed to in part by remodeling of K ϩ currents, as observed in many models of heart failure (67) . In short, our data demonstrate that JNK-induced Cx43 down-regulation has significant functional consequences on the electrical propagation in heart and raises the interesting possibility that activation of JNK signaling in discrete regions of the myocardium may play a key regulatory role in gap junction remodeling that is associated with arrhythmic activity in pathological settings, such as myocardial infarction (68) .
In summary, we have demonstrated the functional effects of targeted activation of JNK in intact heart. Our results suggest that JNK activation plays a role in mediating specific aspects of cardiac remodeling that have important functional implications in a pathological setting. Whereas important new information with regard to the role of JNK signaling in the heart, such as that described in this report, can be gleaned from the MKK7D transgenic model, a limitation to this study is the lack of temporal control over MKK7D expression. Developing transgenic models that allow inducible activation of MKK7D transgene expression in the adult heart, such as that recently reported by us (39) , will allow the elucidation of primary effects of JNK activation from secondary effects of JNK-induced cardiomyopathy and offer further insight into the molecular mechanisms underlying JNK-induced remodeling processes.
